• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by FS Development Corp. II

    12/17/21 2:36:02 PM ET
    $FSII
    Finance
    Get the next $FSII alert in real time by email
    SC 13G 1 d273935dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. ___)*

     

     

    FS Development Corp. II

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    30318F100

    (CUSIP Number)

    December 7, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      Frazier Life Sciences Public Fund L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      634,809 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      634,809 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      634,809 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      3.1% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      FHMLSP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      634,809 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      634,809 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      634,809 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      3.1% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      FHMLSP, L.L.C.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      634,809 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      634,809 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      634,809 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      3.1% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      OO

     

    (1)

    Consists of 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      Frazier Life Sciences X, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      478,891 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      478,891 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      478,891 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.3% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 478,891 shares of Class A Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      FHMLS X, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      478,891 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      478,891 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      478,891 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.3% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 478,891 shares of Class A Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      FHMLS X, L.L.C.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      478,891 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      478,891 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      478,891 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.3% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      OO

     

    (1)

    Consists of 478,891 shares of Class A Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      James N. Topper

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,113,700 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,113,700 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,113,700 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      5.4% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of (i) 478,891 shares of Class A Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      Patrick J. Heron

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,113,700 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,113,700 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,113,700 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      5.4% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of (i) 478,891 shares of Class A Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      Albert Cha

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      634,809 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      634,809 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      634,809 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      3.1% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    CUSIP No. 30318F100

     

      1.    

      Names of Reporting Persons

     

      James Brush

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      634,809 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      634,809 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      634,809 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      3.1% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 634,809 shares of Class A Common Stock held directly by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund L.P.

    (2)

    Based on 20,727,500 shares of Class A Common Stock outstanding on November 23, 2021 as set forth in the Issuer’s Form 10-Q filed with the SEC on November 23, 2021.


    Item 1(a).    Name of Issuer: FS Development Corp. II
    Item 1(b).    Address of Issuer’s Principal Executive Offices: 5959 Horton Street, Suite 300, Emeryville, California 94608
    Item 2(a).   

    Name of Person Filing:

     

    The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

     

    Frazier Life Sciences X, L.P. (“FLS X”)

    FHMLS X, L.P. (“FHMLS-X L.P.”)

    FHMLS X, L.L.C. (“FHMLS-X LLC”)

    Frazier Life Sciences Public Fund L.P. (“FLSPF”)

    FHMLSP, L.P.

    FHMLSP, L.L.C.

    James N. Topper (“Topper”)

    Patrick J. Heron (“Heron”)

    Albert Cha (“Cha”)

    James Brush (“Brush” and together with Topper, Heron and Cha, the “Members”)

    Item 2(b).   

    Address of Principal Business Office or, if none, Residence:

     

    The address and principal business office of the Reporting Persons is:

     

    c/o Frazier Healthcare Partners

    601 Union Street, Suite 3200

    Seattle, Washington 98101

    Item 2(c).    Citizenship:         
       Entities:    FLS X    -    Delaware, U.S.A.
          FHMLS-X L.P.    -    Delaware, U.S.A.
          FHMLS-X LLC    -    Delaware, U.S.A.
          FLSPF    -    Delaware, U.S.A.
          FHMLSP, L.P.    -    Delaware, U.S.A.
          FHMLSP, L.L.C.    -    Delaware, U.S.A.
       Individuals:    Topper    -    United States Citizen
          Heron    -    United States Citizen
          Cha    -    United States Citizen
          Brush    -    United States Citizen
    Item 2(d).    Title of Class of Securities: Class A Common Stock
    Item 2(e).    CUSIP Number: 30318F100
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)   

    ☐   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

    (b)   

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)   

    ☐   Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

    (d)   

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e)   

    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f)   

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)   

    ☐   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    (h)   

    ☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)   

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j)   

    ☐   A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)   

    ☐   Group, in accordance with §240.13d–1(b)(1)(ii)(K).

       If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____
    Item 4.    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    (a)    Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.
    (b)    Percent of Class: See Row 11 of cover page for each Reporting Person
    (c)    Number of shares as to which the person has:
       (i)    Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
       (ii)    Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
       (iii)    Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
       (iv)    Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

     

    Item 5.    Ownership of 5 Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.    Identification and Classification of Members of the Group

    Each member of the group is identified on Exhibit A to this Schedule 13G.

     

    Item 9.    Notice of Dissolution of a Group

    Not applicable.

     

    Item 10.    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: December 17, 2021     FRAZIER LIFE SCIENCES X, L.P.
        By FHMLS X, L.P., its general partner
        By FHMLS X, L.L.C., its general partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: December 17, 2021     FHMLS X, L.P.
        By FHMLS X, L.L.C., its general partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: December 17, 2021     FHMLS X, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: December 17, 2021     FRAZIER LIFE SCIENCES PUBLIC FUND L.P.
        By: FHMLSP, L.P., its General Partner
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: December 17, 2021     FHMLSP, L.P.
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: December 17, 2021     FHMLSP, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: December 17, 2021     By:  

    *

          James N. Topper
    Date: December 17, 2021     By:  

    *

          Patrick J. Heron


    Date: December 17, 2021     By:  

    **

          Albert Cha
    Date: December 17, 2021     By:  

    **

          James Brush
    Date: December 17, 2021     *By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, as Attorney-in-Fact

     

    *

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on February 24, 2017.

    **

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.


    Exhibit Index

    Exhibit A - Agreement regarding filing of joint Schedule 13G.

     

    Get the next $FSII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FSII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FSII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

    Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of funds held in FS Development Corp. II's trust account and concurrent PIPE financing of $75 million Business combination transaction with FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital, completed on December 23, 2021 Combined company renamed Pardes Biosciences, Inc. Common stock commences trading today under ticker symbol "PRDS" on the Nasdaq Global Market CARLSBAD, Calif. and BERKELEY, Calif., Dec. 27, 2021 (G

    12/27/21 7:00:00 AM ET
    $FSII
    Finance

    FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

    Proposed merger heads to shareholder vote on December 23rd as ongoing Phase I trial shows potential for unboosted oral regimen In advance of the shareholder vote for the business combination between FS Development Corp. II (NASDAQ:FSII) and Pardes Biosciences, Inc. ("Pardes"), the CEOs of both companies are sharing their thoughts on the COVID-19 public health emergency and how they expect the combined company to play an important role in addressing one of the biggest health crises of our time. "We believe that direct-acting antivirals against coronavirus that are taken orally – such as our PBI-0451 – will become increasingly important in a world where SARS-CoV-2 may become endemic. This e

    12/21/21 7:00:00 AM ET
    $FSII
    Finance

    FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

    FS Development Corp. II, a Delaware corporation (the "Company") (NASDAQ:FSII), announced today that its registration statement on Form S-4 (File No. 333-258442) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with Pardes Biosciences, Inc. ("Pardes"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the "Special Meeting") of the Company's stockholders to be held on December 23, 2021 in connection with the Business Combination. The proxy statement/prospectus is being mai

    12/1/21 11:38:00 AM ET
    $FSII
    Finance

    $FSII
    SEC Filings

    View All

    FS Development Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

    1/7/22 7:00:50 AM ET
    $FSII
    Finance

    FS Development Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Registrant’s Certifying Accountant, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Other Events

    8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

    12/30/21 4:55:34 PM ET
    $FSII
    Finance

    FS Development Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

    12/27/21 7:09:01 AM ET
    $FSII
    Finance

    $FSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Tananbaum James B. converted options into 4,941,250 shares (Amendment)

    4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

    12/30/21 4:30:19 PM ET
    $FSII
    Finance

    SEC Form 4: Pakianathan Deepika converted options into 30,000 shares (Amendment)

    4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

    12/30/21 4:00:26 PM ET
    $FSII
    Finance

    SEC Form 4: Hughes Owen converted options into 30,000 shares (Amendment)

    4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

    12/30/21 4:00:23 PM ET
    $FSII
    Finance

    $FSII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by FS Development Corp. II

    SC 13G - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

    1/10/22 5:00:36 PM ET
    $FSII
    Finance

    SEC Form SC 13G/A filed by FS Development Corp. II (Amendment)

    SC 13G/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

    1/10/22 2:12:29 PM ET
    $FSII
    Finance

    SEC Form SC 13D filed by FS Development Corp. II

    SC 13D - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

    12/30/21 5:09:44 PM ET
    $FSII
    Finance